Novocure Phase 3 Clinical Trial Met Primary Endpoint

 The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients treated with supportive care alone

Patients treated with TTFields therapy experienced prolonged quality of life deterioration-free survival and TTFields therapy was well-tolerated

Data from the METIS trial to be presented today during the 2024 ASCO Annual Meeting

https://www.businesswire.com/news/home/20240603817216/en/METIS-Phase-3-Clinical-Trial-Met-Primary-Endpoint-Significantly-Delaying-Time-to-Intracranial-Progression-with-Improved-Quality-of-Life-Deterioration-Free-Survival